奥拉帕利作为美国新诊断晚期卵巢癌BRCA1/2突变女性维持治疗的成本效益
本研究从美国第三方支付者视角,评估奥拉帕利单药一线维持治疗对比监测在新诊断晚期卵巢癌BRCA1/2突变女性中的成本效益。采用三状态分区生存模型,基于III期SOLO1试验数据外推, lifetime horizon 50年。结果显示奥拉帕利增加3.63生命年和2.93质量调整生命年,增量总成本152,545美元,增量成本效益比分别为每生命年42,032美元和每QALY 51,986美元,在100,000美元/QALY阈值下具有成本效益的概率为99%。
要点
- 奥拉帕利一线维持对比监测增加3.63生命年和2.93质量调整生命年。
- 增量总成本152,545美元,每QALY增量成本51,986美元。
- 在100,000美元/QALY阈值下,奥拉帕利具有成本效益的概率为99%。
核心结论
- 对比监测,奥拉帕利增加新诊断晚期卵巢癌伴胚系或体细胞BRCA突变女性的生命年和质量调整生命年。
- 从美国第三方支付者视角,奥拉帕利为这些女性提供具有成本效益的维持治疗选择。
研究设计与样本
- 从美国第三方支付者视角评估奥拉帕利单药一线维持治疗对比监测的成本效益。
- 构建三状态(无进展、进展疾病、死亡)分区生存模型,时间跨度50年。
- 应用分段模型对III期SOLO1试验数据进行生存结局外推。
- 健康状态效用和不良事件负效用来自文献和SOLO1,治疗成本、不良事件成本和医疗成本来自公开数据库、SOLO1和真实世界数据。
- 进行单因素确定性和概率敏感性分析。
主要发现
- 在50年时间跨度内,奥拉帕利对比监测增加3.63生命年和2.93质量调整生命年,增量总成本152,545美元。
- 奥拉帕利每获得生命年增量成本为42,032美元,每获得质量调整生命年增量成本为51,986美元。
- 在一系列输入和情景下,增量成本效益比保持在100,000美元以下。
- 在概率敏感性分析中,以100,000美元/QALY为阈值,奥拉帕利具有成本效益的概率为99%。
关键数值与推荐
- 增量成本效益比:每生命年42,032美元,每质量调整生命年51,986美元。
- 在100,000美元/QALY阈值下,奥拉帕利具有成本效益的概率为99%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluated the cost-effectiveness of olaparib monotherapy in the first-line maintenance setting vs. surveillance in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation from a US third-party payer perspective. METHODS: A three-state (progression free, progressed disease, and death) partitioned survival model over a 50-year lifetime horizon was developed. Piecewise models were applied to data from the phase III trial SOLO1 to extrapolate survival outcomes. Health state utilities and adverse event disutilities were obtained from literature and SOLO1. Treatment costs, adverse event costs, and medical costs associated with health states were obtained from publicly available databases, SOLO1, and real-world data. Time on treatment was estimated using the data from SOLO1. Incremental costs per quality-adjusted life year (QALY) and life year (LY) gained were estimated. One-way deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Over a lifetime horizon, olaparib was associated with an additional 3.63 LYs and 2.93 QALYs, and an incremental total cost of $152,545 vs. surveillance. Incremental cost per LY gained and per QALY gained for olaparib were $42,032 and $51,986, respectively. The incremental cost-effectiveness ratios remained below $100,000 across a range of inputs and scenarios. In the PSA, the probability of olaparib being cost-effective at a $100,000 per QALY threshold was 99%. CONCLUSIONS: Compared to surveillance, olaparib increases both the LYs and QALYs of women with newly diagnosed advanced ovarian cancer and with a germline or somatic BRCA mutation. Olaparib offers a cost-effective maintenance option for these women from a US third-party payer perspective.
引用
- Muston D, Hettle R, Monberg M, et al. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020. PMID: 32951894. doi:10.1016/j.ygyno.2020.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。